炎琥宁注射液联合抗病毒治疗邪毒侵心型急性病毒性心肌炎的疗效影响

Efficacy of Yanhuning Injection Combined with Antiviral Therapy in Treating Acute Viral Myocarditis of Pathogenic Toxin Invading Heart Syndrome

目的:探讨炎琥宁注射液联合抗病毒治疗邪毒侵心型急性病毒性心肌炎(Acute Viral Myocarditis,VMC)的疗效及对患者血清中巨噬细胞移动抑制因子(Macrophage Mobile Inhibiting Factor,MIF)和白细胞介素(Interleukin,IL)-6水平的影响。方法:选取2012年2月至2016年9月陕西省人民医院收治的急性病毒性心肌炎患者300例,随机分为观察组和对照组,每组150例。对照组采取常规干预措施和抗病毒治疗。观察组在对照组基础上予炎琥宁注射液治疗,2次/d。2组患者给予4周的疗效观察。比较2组临床症状评分、血清肌钙蛋白I(Serum troponin I,cTnI)和心型游离脂肪酸结合蛋白(Fatty Acid Binding Protein,H-FABP)水平。分析2组临床治疗效果。检测2组血清中MIF和IL-6水平。结果:治疗后,观察组的症状评分、血清中cTnI和H-FABP水平显著少于对照组,差异有统计学意义(P<0.01)。观察组总有效率为88.59%,明显高于对照组为81.08%,差异有统计学意义(P<0.05)。观察组治疗后患者血清中MIF和IL-6水平显著低于对照组,差异有统计学意义(P<0.01)。结论:炎琥宁注射液联合抗病毒治疗治疗邪毒侵心型急性VMC疗效明显,下调患者血清中MIF和IL-6水平可能与其疗效有关。

Objective： To investigate the efficacy of Yanhuning injection combined with antiviral therapy in treating acute viral myocarditis（ VMC） of pathogenic toxin invading heart syndrome and the influence on serum levels of macrophage migration inhibition factor（ MIF） and interleukin（ IL）-6. Methods： A total of 300 patients of acute VMC were randomly divided into control group（ 150 cases） and treatment group（ 150 cases）. The control group was treated with routine therapy and antiviral therapy. Based on control group,the observation group was given with Yanhuning injection,2 times/d. Courses were for four weeks in both groups.Scores of symptoms and serum levels of cardiac troponin i（ cTnI） and Heart-type fatty acid-binding proteins（ H-FABP） were compared in 2 groups. Efficacy was analyzed in 2 groups. Serum levels of MIF and IL-6 were measured in both groups. Results： After treatment,symptoms score and serum levels of cTnI and H-FABP were significantly lower than those of observation group（ P〈0. 01）. Efficacy rate of observation group was 88. 59%,which was remarkably higher than control group 81. 08%（ P〈0. 05）.Serum levels of MIF and IL-6 of observation group were evidently lower than those of control group（ P〈0. 01）. Conclusion： Efficacy of Yanhuning injection combined with antiviral therapy in treating acute VMC of pathogenic toxin invading heart syndrome,which is related to down-regualtion of serum levels of MIF and IL-6.